Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 2.42
- Piotroski Score 4.00
- Grade Neutral
- Symbol (CERT)
- Company Certara, Inc.
- Price $11.09
- Changes Percentage (0.91%)
- Change $0.1
- Day Low $11.06
- Day High $11.39
- Year High $19.87
Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/05/2024
- Fiscal Year End N/A
- Average Stock Price Target $20.00
- High Stock Price Target $28.00
- Low Stock Price Target $16.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.39
- Trailing P/E Ratio -43.54
- Forward P/E Ratio -43.54
- P/E Growth -43.54
- Net Income $-55,357,000
Income Statement
Quarterly
Annual
Latest News of CERT
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Dell Technologies Inc. (DELL): Susquehanna Initiates Coverage with Neutral Rating, Citing Uncertainty in AI Hardware and Services Strategy
A list of 30 AI News Investors Should Not Miss includes Dell Technologies Inc. (NYSE:DELL) and its position against other AI stocks. The article discusses the latest developments in AI data centers an...
By Yahoo! Finance | 11 hours ago -
Why this 'Real Housewives' star is over certain dating apps
RHOC star Noella Bergener is opting for Seeking.com over mainstream dating apps due to its niche approach. Research suggests that stepping out of one's comfort zone is key to combatting dating fatigue...
By Newsweek | 1 day ago -
Albemarle Stock Surge Despite Uncertainty of Rio Tinto's Lithium Acquisitions
Rio Tinto Plc is considering acquiring major players in the lithium market, Albemarle and Arcadium Lithium, due to the rising demand for lithium batteries in electric vehicles. The potential acquisiti...
By Yahoo! Finance | 1 day ago
